We have updated our terms and conditions and privacy policy
Click “Continue” to accept and continue with ET HealthWorld
Dear user,
ET HealthWorld privacy and cookie policy has been updated to align with the new data regulations in European Union. Please review and accept these changes below to continue using the website.
You can see our privacy policy & our cookie policy. We use cookies to ensure the best experience for you on our website.
If you choose to ignore this message, we’ll assume that you are happy to receive all cookies on ET HealthWorld.
One year on, vaccines still most acceptable weapon against Covid-19
COVID-19: India’s R value drops to 2.2 between January 7 and 13, shows IIT Madras analysis
Rebooting Cancer Awareness
The unsung hero in faster holistic recovery
Technological Disruption in Indian Health & Pharma
Do you think you are up for the challenge?
Holistic Solutions For A Healthier India
17 July
Adopting-Dynamic-Technologies
The technology of ART is great and provides success stories but there is scope of improvement in the newly passed bill of ART. The bill needs to be practical in approach, so that it can be embraced by the willing people without any hesitation.
Recommended by Colombia
125000+ Industry Leaders read it everyday
The World Health Organization approved two new Covid-19 treatments on Friday, growing the arsenal of tools along with vaccines to stave off severe illness and death from the virus.
Over a dozen companies, including Hetero, Sun Pharma, Natco and Dr Reddy’s are in the process of rolling out the oral therapy developed by Merck and and its partner, Ridgeback Biotherapeutics, at prices ranging between Rs 1,500 and Rs 2,500 for the complete treatment, sources told TOI.
We have various options to advertise with us including Events, Advertorials, Banners, Mailers, Webinars etc.
Please contact us to know more details.
Get ETHealthworld‘s top stories every morning in your email inbox.
125000+ Industry Leaders read it everyday
Follow @ETHealthworld for the latest news, insider access to events and more.
